[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Praxis Precision Medicines (PRAX) insider filing: the company’s General Counsel and Secretary reported multiple stock option exercises and related share sales on 11/20/2025. The officer exercised options to acquire blocks of common stock at exercise prices of $44.4, $56.94, $83.85 and $133.65, then sold shares in several transactions, including 1,714 shares at a weighted average price of $190.863, 13,339 shares at $192.533, 977 shares at $193.233 and 9,100 shares at $194.3. After these transactions, the reporting person directly owned 20,831.667 shares of Praxis common stock, along with remaining stock options over additional shares that vest over time. The filing notes that the transactions were effected for estate planning purposes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nemiroff Alex

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		M		1,714	A	$83.85	22,545.667	D
Common Stock	11/20/2025		M		6,230	A	$133.65	28,775.667	D
Common Stock	11/20/2025		M		2,434	A	$44.4	31,209.667	D
Common Stock	11/20/2025		M		5,652	A	$44.4	36,861.667	D
Common Stock	11/20/2025		M		9,100	A	$56.94	45,961.667	D
Common Stock	11/20/2025		S		1,714	D	$190.863(1)	44,247.667	D
Common Stock	11/20/2025		S		13,339	D	$192.533(2)	30,908.667	D
Common Stock	11/20/2025		S		977	D	$193.233(3)	29,931.667	D
Common Stock	11/20/2025		S		9,100	D	$194.3	20,831.667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$83.85	11/20/2025		M			1,714	(4)	06/04/2030	Common Stock	1,714	$0.00	0	D
Stock Option (Right to Buy)	$133.65	11/20/2025		M			6,230	(5)	09/13/2030	Common Stock	6,230	$0.00	0	D
Stock Option (Right to Buy)	$44.4	11/20/2025		M			2,434	01/12/2023	01/12/2033	Common Stock	2,434	$0.00	0	D
Stock Option (Right to Buy)	$44.4	11/20/2025		M			5,652	(6)	01/12/2033	Common Stock	5,652	$0.00	2,347	D
Stock Option (Right to Buy)	$56.94	11/20/2025		M			9,100	(7)	07/29/2034	Common Stock	9,100	$0.00	19,717	D

Explanation of Responses:

1. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $190.720 to $191.540. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

2. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $192.003 to $193.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

3. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $193.010 to $193.960. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

4. This option was fully vested as of January 1, 2024.

5. This option was fully vested as of September 9, 2024.

6. The shares underlying this stock option vested as to 25% on January 12, 2024 and the remaining shares vest in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date.

7. The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the Reporting Person's continued service through each vesting date.

Remarks:

The transactions reported in this Form 4 were effected for estate planning purposes.

	/s/ Alex Nemiroff	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did PRAX insider Alex Nemiroff report in this Form 4 filing?

The General Counsel and Secretary of Praxis Precision Medicines (PRAX) reported exercising multiple stock options and selling shares of common stock on 11/20/2025, while retaining a significant direct shareholding and remaining stock options.

How many PRAX shares does the reporting person own after the 11/20/2025 transactions?

Following the reported transactions on 11/20/2025, the reporting person directly owned 20,831.667 shares of Praxis Precision Medicines common stock.

At what prices were PRAX shares sold in this insider transaction report?

The filing shows weighted average sale prices of $190.863, $192.533, and $193.233, with an additional sale at $194.3 per share, each reflecting multiple trades within narrow price ranges.

What stock options did the PRAX insider exercise on 11/20/2025?

The officer exercised stock options to buy Praxis common stock at exercise prices of $83.85, $133.65, $44.4, and $56.94, covering several option grants with different vesting and expiration dates.

Were the PRAX insider transactions related to a trading plan or estate planning?

The Form 4 indicates that the transactions reported were effected for estate planning purposes. The form also includes an option to indicate Rule 10b5-1 plan transactions, consistent with standard reporting format.

How are the sale prices in the PRAX Form 4 described?

For several sales, the filing reports weighted average prices and states the shares were sold in multiple transactions within specified price ranges, with an undertaking to provide detailed breakdowns upon request.